Piperacillin (English Wikipedia)

Analysis of information sources in references of the Wikipedia article "Piperacillin" in English language version.

refsWebsite

Global rank English rank

61nih.gov

4^th place

51doi.org

2^nd place

17semanticscholar.org

11^th place

8^th place

1books.google.com

3^rd place

1handle.net

102^nd place

76^th place

1figshare.com

5,893^rd place

3,320^th place

books.google.com

Fischer J, Ganellin CR (2006). Analogue-based Drug Discovery. John Wiley & Sons. p. 491. ISBN 9783527607495.

doi.org

Tan JS, File TM (July 1995). "Antipseudomonal penicillins". The Medical Clinics of North America. 79 (4): 679–93. doi:10.1016/s0025-7125(16)30032-3. PMID 7791416.
Zhanel GG, DeCorby M, Laing N, Weshnoweski B, Vashisht R, Tailor F, et al. (April 2008). "Antimicrobial-resistant pathogens in intensive care units in Canada: results of the Canadian National Intensive Care Unit (CAN-ICU) study, 2005-2006". Antimicrobial Agents and Chemotherapy. 52 (4): 1430–7. doi:10.1128/AAC.01538-07. PMC 2292546. PMID 18285482.
Schumock GT, Li EC, Suda KJ, Wiest MD, Stubbings J, Matusiak LM, et al. (May 2015). "National trends in prescription drug expenditures and projections for 2015". American Journal of Health-System Pharmacy. 72 (9): 717–36. doi:10.2146/ajhp140849. PMID 25873620.
Schlossberg D, Samuel R (2017-10-04). Antibiotics Manual. doi:10.1002/9781119220787. ISBN 9781119220787.
Klastersky JA, ed. (1997). Febrile Neutropenia. Berlin, Heidelberg: Springer Berlin Heidelberg. doi:10.1007/978-3-642-60443-0. ISBN 978-3-540-61230-8. S2CID 34848917.
Westphal JF, Brogard JM (January 1999). "Biliary tract infections: a guide to drug treatment". Drugs. 57 (1): 81–91. doi:10.2165/00003495-199957010-00007. PMID 9951953. S2CID 46953299.
Perry CM, Markham A (May 1999). "Piperacillin/tazobactam: an updated review of its use in the treatment of bacterial infections". Drugs. 57 (5): 805–43. doi:10.2165/00003495-199957050-00017. PMID 10353303. S2CID 209143536.
Joshi M, Bernstein J, Solomkin J, Wester BA, Kuye O (March 1999). "Piperacillin/tazobactam plus tobramycin versus ceftazidime plus tobramycin for the treatment of patients with nosocomial lower respiratory tract infection. Piperacillin/tazobactam Nosocomial Pneumonia Study Group". The Journal of Antimicrobial Chemotherapy. 43 (3): 389–97. doi:10.1093/jac/43.3.389. PMID 10223595.
Alvarez-Lerma F, Insausti-Ordeñana J, Jordá-Marcos R, Maraví-Poma E, Torres-Martí A, Nava J, et al. (March 2001). "Efficacy and tolerability of piperacillin/tazobactam versus ceftazidime in association with amikacin for treating nosocomial pneumonia in intensive care patients: a prospective randomized multicenter trial". Intensive Care Medicine. 27 (3): 493–502. doi:10.1007/s001340000846. PMID 11355117. S2CID 587826.
Joshi M, Metzler M, McCarthy M, Olvey S, Kassira W, Cooper A (September 2006). "Comparison of piperacillin/tazobactam and imipenem/cilastatin, both in combination with tobramycin, administered every 6 h for treatment of nosocomial pneumonia". Respiratory Medicine. 100 (9): 1554–65. doi:10.1016/j.rmed.2006.01.004. PMID 16487695.
Schmitt DV, Leitner E, Welte T, Lode H (June 2006). "Piperacillin/tazobactam vs imipenem/cilastatin in the treatment of nosocomial pneumonia--a double blind prospective multicentre study". Infection. 34 (3): 127–34. doi:10.1007/s15010-006-5020-0. PMID 16804655. S2CID 43485365.
Lau WK, Mercer D, Itani KM, Nicolau DP, Kuti JL, Mansfield D, et al. (November 2006). "Randomized, open-label, comparative study of piperacillin-tazobactam administered by continuous infusion versus intermittent infusion for treatment of hospitalized patients with complicated intra-abdominal infection". Antimicrobial Agents and Chemotherapy. 50 (11): 3556–61. doi:10.1128/AAC.00329-06. PMC 1635208. PMID 16940077.
Kaufman SE, Donnell RW, Hickey WS (August 2011). "Rationale and evidence for extended infusion of piperacillin-tazobactam". American Journal of Health-System Pharmacy. 68 (16): 1521–6. doi:10.2146/ajhp100694. PMID 21817083.
Wolf MF, Simon A (January 2009). "The use of piperacillin-tazobactam in neonatal and paediatric patients". Expert Opinion on Drug Metabolism & Toxicology. 5 (1): 57–69. doi:10.1517/17425250802614688. PMID 19236229. S2CID 72928444.
Gin A, Dilay L, Karlowsky JA, Walkty A, Rubinstein E, Zhanel GG (June 2007). "Piperacillin-tazobactam: a beta-lactam/beta-lactamase inhibitor combination". Expert Review of Anti-Infective Therapy. 5 (3): 365–83. doi:10.1586/14787210.5.3.365. PMID 17547502. S2CID 68837323.
Benli A, Şimşek-Yavuz S, Başaran S, Çağatay A, Özsüt H, Eraksoy H (November 2018). "Hematologic Adverse Effects of Prolonged Piperacillin-Tazobactam Use in Adults". Turkish Journal of Haematology. 35 (4): 290–295. doi:10.4274/tjh.2018.0127. PMC 6256823. PMID 29856362.
Page MG (2012). "Beta-Lactam Antibiotics". In Dougherty TJ, Pucci MJ (eds.). Antibiotic Discovery and Development. Boston, MA: Springer US. pp. 79–117. doi:10.1007/978-1-4614-1400-1_3. ISBN 978-1-4614-1399-8.
Dowling PM (July 2013). "Peptide antibiotics: polymyxins, glycopeptides, bacitracin, and fosfomycin.". In Giguère S, Prescott JF, Dowling PM (eds.). Antimicrobial Therapy in Veterinary Medicine. Wiley Blackwell. pp. 189–192. doi:10.1002/9781118675014. ISBN 9780470963029.
Zarychanski R, Wlodarczyk K, Ariano R, Bow E (July 2006). "Pharmacokinetic interaction between methotrexate and piperacillin/tazobactam resulting in prolonged toxic concentrations of methotrexate". The Journal of Antimicrobial Chemotherapy. 58 (1): 228–30. doi:10.1093/jac/dkl196. PMID 16717053.
Iven H, Brasch H (1986). "Influence of the antibiotics piperacillin, doxycycline, and tobramycin on the pharmacokinetics of methotrexate in rabbits". Cancer Chemotherapy and Pharmacology. 17 (3): 218–22. doi:10.1007/BF00256687. PMID 3742705. S2CID 25441195.
Wilke MS, Lovering AL, Strynadka NC (October 2005). "Beta-lactam antibiotic resistance: a current structural perspective". Current Opinion in Microbiology. 8 (5): 525–33. doi:10.1016/j.mib.2005.08.016. PMID 16129657.
Samaha-Kfoury JN, Araj GF (November 2003). "Recent developments in beta lactamases and extended spectrum beta lactamases". BMJ. 327 (7425): 1209–13. doi:10.1136/bmj.327.7425.1209. PMC 274061. PMID 14630759.
Yang Y, Rasmussen BA, Shlaes DM (August 1999). "Class A beta-lactamases--enzyme-inhibitor interactions and resistance". Pharmacology & Therapeutics. 83 (2): 141–51. doi:10.1016/S0163-7258(99)00027-3. PMID 10511459.
Hayashi Y, Roberts JA, Paterson DL, Lipman J (August 2010). "Pharmacokinetic evaluation of piperacillin-tazobactam". Expert Opinion on Drug Metabolism & Toxicology. 6 (8): 1017–31. doi:10.1517/17425255.2010.506187. PMID 20636224. S2CID 38067522.
Rybkine T, Mainardi JL, Sougakoff W, Collatz E, Gutmann L (July 1998). "Penicillin-binding protein 5 sequence alterations in clinical isolates of Enterococcus faecium with different levels of beta-lactam resistance". The Journal of Infectious Diseases. 178 (1): 159–63. doi:10.1086/515605. PMID 9652435.
Palmer SM, Rybak MJ (April 1997). "An evaluation of the bactericidal activity of ampicillin/sulbactam, piperacillin/tazobactam, imipenem or nafcillin alone and in combination with vancomycin against methicillin-resistant Staphylococcus aureus (MRSA) in time-kill curves with infected fibrin clots". The Journal of Antimicrobial Chemotherapy. 39 (4): 515–8. doi:10.1093/jac/39.4.515. PMID 9145825.
Grebe T, Hakenbeck R (April 1996). "Penicillin-binding proteins 2b and 2x of Streptococcus pneumoniae are primary resistance determinants for different classes of beta-lactam antibiotics". Antimicrobial Agents and Chemotherapy. 40 (4): 829–34. doi:10.1128/AAC.40.4.829. PMC 163214. PMID 8849235.
Rice LB, Carias LL, Hujer AM, Bonafede M, Hutton R, Hoyen C, et al. (February 2000). "High-level expression of chromosomally encoded SHV-1 beta-lactamase and an outer membrane protein change confer resistance to ceftazidime and piperacillin-tazobactam in a clinical isolate of Klebsiella pneumoniae". Antimicrobial Agents and Chemotherapy. 44 (2): 362–7. doi:10.1128/AAC.44.2.362-367.2000. PMC 89684. PMID 10639363.
Poole K (September 2004). "Resistance to beta-lactam antibiotics". Cellular and Molecular Life Sciences. 61 (17): 2200–23. doi:10.1007/s00018-004-4060-9. PMC 11138534. PMID 15338052. S2CID 25289147.
Aronoff GR, Sloan RS, Brier ME, Luft FC (1983). "The effect of piperacillin dose on elimination kinetics in renal impairment". European Journal of Clinical Pharmacology. 24 (4): 543–7. doi:10.1007/BF00609901. PMID 6222908. S2CID 262219.
Sörgel F, Kinzig M (July 1994). "Pharmacokinetic characteristics of piperacillin/tazobactam". Intensive Care Medicine. 20 Suppl 3 (S3): S14-20. doi:10.1007/bf01745246. PMID 7962984. S2CID 27422742.
Welling PG, Craig WA, Bundtzen RW, Kwok FW, Gerber AU, Madsen PO (June 1983). "Pharmacokinetics of piperacillin in subjects with various degrees of renal function". Antimicrobial Agents and Chemotherapy. 23 (6): 881–7. doi:10.1128/aac.23.6.881. PMC 184992. PMID 6225390.
Wise R, Logan M, Cooper M, Andrews JM (June 1991). "Pharmacokinetics and tissue penetration of tazobactam administered alone and with piperacillin". Antimicrobial Agents and Chemotherapy. 35 (6): 1081–4. doi:10.1128/AAC.35.6.1081. PMC 284290. PMID 1656853.
Westphal JF, Brogard JM, Caro-Sampara F, Adloff M, Blicklé JF, Monteil H, et al. (August 1997). "Assessment of biliary excretion of piperacillin-tazobactam in humans". Antimicrobial Agents and Chemotherapy. 41 (8): 1636–40. doi:10.1128/aac.41.8.1636. PMC 163977. PMID 9257733.
Bryson HM, Brogden RN (March 1994). "Piperacillin/tazobactam. A review of its antibacterial activity, pharmacokinetic properties and therapeutic potential". Drugs. 47 (3): 506–35. doi:10.2165/00003495-199447030-00008. PMID 7514977. S2CID 209144038.
Kinzig M, Sörgel F, Brismar B, Nord CE (September 1992). "Pharmacokinetics and tissue penetration of tazobactam and piperacillin in patients undergoing colorectal surgery". Antimicrobial Agents and Chemotherapy. 36 (9): 1997–2004. doi:10.1128/aac.36.9.1997. PMC 192425. PMID 1329637.
Craig WA (January 1998). "Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men". Clinical Infectious Diseases. 26 (1): 1–10, quiz 11–2. doi:10.1086/516284. PMID 9455502.
Turnidge JD (July 1998). "The pharmacodynamics of beta-lactams". Clinical Infectious Diseases. 27 (1): 10–22. doi:10.1086/514622. PMID 9675443.
Burgess DS, Waldrep T (July 2002). "Pharmacokinetics and pharmacodynamics of piperacillin/tazobactam when administered by continuous infusion and intermittent dosing". Clinical Therapeutics. 24 (7): 1090–104. doi:10.1016/s0149-2918(02)80021-2. PMID 12182254.
Buck C, Bertram N, Ackermann T, Sauerbruch T, Derendorf H, Paar WD (January 2005). "Pharmacokinetics of piperacillin-tazobactam: intermittent dosing versus continuous infusion". International Journal of Antimicrobial Agents. 25 (1): 62–7. doi:10.1016/j.ijantimicag.2004.08.012. PMID 15620828.
Occhipinti DJ, Pendland SL, Schoonover LL, Rypins EB, Danziger LH, Rodvold KA (November 1997). "Pharmacokinetics and pharmacodynamics of two multiple-dose piperacillin-tazobactam regimens". Antimicrobial Agents and Chemotherapy. 41 (11): 2511–7. doi:10.1128/AAC.41.11.2511. PMC 164153. PMID 9371358.
Ong CT, Kuti JL, Nicolau DP (2005). "Pharmacodynamic modeling of imipenem-cilastatin, meropenem, and piperacillin-tazobactam for empiric therapy of skin and soft tissue infections: a report from the OPTAMA Program". Surgical Infections. 6 (4): 419–26. doi:10.1089/sur.2005.6.419. PMID 16433606.
Kotapati S, Kuti JL, Nicolau DP (2005). "Pharmacodynamic modeling of beta-lactam antibiotics for the empiric treatment of secondary peritonitis: a report from the OPTAMA program". Surgical Infections. 6 (3): 297–304. doi:10.1089/sur.2005.6.297. PMID 16201939.
Maglio D, Kuti JL, Nicolau DP (July 2005). "Simulation of antibiotic pharmacodynamic exposure for the empiric treatment of nosocomial bloodstream infections: a report from the OPTAMA program". Clinical Therapeutics. 27 (7): 1032–42. doi:10.1016/j.clinthera.2005.07.004. PMID 16154482.
Sun HK, Kuti JL, Nicolau DP (October 2005). "Pharmacodynamics of antimicrobials for the empirical treatment of nosocomial pneumonia: a report from the OPTAMA Program". Critical Care Medicine. 33 (10): 2222–7. doi:10.1097/01.CCM.0000181528.88571.9B. PMID 16215374. S2CID 27349260.
Mattoes HM, Capitano B, Kim MK, Xuan D, Quintiliani R, Nightingale CH, et al. (May 2002). "Comparative pharmacokinetic and pharmacodynamic profile of piperacillin/tazobactam 3.375G Q4H and 4.5G Q6H". Chemotherapy. 48 (2): 59–63. doi:10.1159/000057663. PMID 12011536. S2CID 25721950.
Li C, Kuti JL, Nightingale CH, Mansfield DL, Dana A, Nicolau DP (August 2005). "Population pharmacokinetics and pharmacodynamics of piperacillin/tazobactam in patients with complicated intra-abdominal infection". The Journal of Antimicrobial Chemotherapy. 56 (2): 388–95. doi:10.1093/jac/dki243. PMID 16002420.
Lodise TP, Lomaestro BM, Drusano GL (September 2006). "Application of antimicrobial pharmacodynamic concepts into clinical practice: focus on beta-lactam antibiotics: insights from the Society of Infectious Diseases Pharmacists". Pharmacotherapy. 26 (9): 1320–32. doi:10.1592/phco.26.9.1320. PMID 16945055. S2CID 196393077.
Lodise TP, Lomaestro B, Rodvold KA, Danziger LH, Drusano GL (December 2004). "Pharmacodynamic profiling of piperacillin in the presence of tazobactam in patients through the use of population pharmacokinetic models and Monte Carlo simulation". Antimicrobial Agents and Chemotherapy. 48 (12): 4718–24. doi:10.1128/AAC.48.12.4718-4724.2004. PMC 529233. PMID 15561849.
Reese AM, Frei CR, Burgess DS (August 2005). "Pharmacodynamics of intermittent and continuous infusion piperacillin/tazobactam and cefepime against extended-spectrum beta-lactamase-producing organisms". International Journal of Antimicrobial Agents. 26 (2): 114–9. doi:10.1016/j.ijantimicag.2005.06.004. PMID 16029947.
Essack SY (2001). "The Development of β-Lactam Antibiotics in Response to the Evolution of β-Lactamases 6". Pharmaceutical Research. 18 (10): 1391–1399. doi:10.1023/A:1012272403776. PMID 11697463. S2CID 34318096.

figshare.com

Schumock GT, Li EC, Suda KJ, Wiest MD, Stubbings J, Matusiak LM, et al. (May 2015). "National trends in prescription drug expenditures and projections for 2015". American Journal of Health-System Pharmacy. 72 (9): 717–36. doi:10.2146/ajhp140849. PMID 25873620.

handle.net

hdl.handle.net

World Health Organization (2019). Critically important antimicrobials for human medicine (6th revision ed.). Geneva: World Health Organization. hdl:10665/312266. ISBN 9789241515528.

nih.gov

pubmed.ncbi.nlm.nih.gov

Tan JS, File TM (July 1995). "Antipseudomonal penicillins". The Medical Clinics of North America. 79 (4): 679–93. doi:10.1016/s0025-7125(16)30032-3. PMID 7791416.
Zhanel GG, DeCorby M, Laing N, Weshnoweski B, Vashisht R, Tailor F, et al. (April 2008). "Antimicrobial-resistant pathogens in intensive care units in Canada: results of the Canadian National Intensive Care Unit (CAN-ICU) study, 2005-2006". Antimicrobial Agents and Chemotherapy. 52 (4): 1430–7. doi:10.1128/AAC.01538-07. PMC 2292546. PMID 18285482.
Schumock GT, Li EC, Suda KJ, Wiest MD, Stubbings J, Matusiak LM, et al. (May 2015). "National trends in prescription drug expenditures and projections for 2015". American Journal of Health-System Pharmacy. 72 (9): 717–36. doi:10.2146/ajhp140849. PMID 25873620.
National Collaborating Centre for Cancer (2012). "Neutropenic Sepsis: Prevention and Management of Neutropenic Sepsis in Cancer Patients". PMID 26065059. {{cite journal}}: Cite journal requires |journal= (help)
Westphal JF, Brogard JM (January 1999). "Biliary tract infections: a guide to drug treatment". Drugs. 57 (1): 81–91. doi:10.2165/00003495-199957010-00007. PMID 9951953. S2CID 46953299.
Perry CM, Markham A (May 1999). "Piperacillin/tazobactam: an updated review of its use in the treatment of bacterial infections". Drugs. 57 (5): 805–43. doi:10.2165/00003495-199957050-00017. PMID 10353303. S2CID 209143536.
Joshi M, Bernstein J, Solomkin J, Wester BA, Kuye O (March 1999). "Piperacillin/tazobactam plus tobramycin versus ceftazidime plus tobramycin for the treatment of patients with nosocomial lower respiratory tract infection. Piperacillin/tazobactam Nosocomial Pneumonia Study Group". The Journal of Antimicrobial Chemotherapy. 43 (3): 389–97. doi:10.1093/jac/43.3.389. PMID 10223595.
Alvarez-Lerma F, Insausti-Ordeñana J, Jordá-Marcos R, Maraví-Poma E, Torres-Martí A, Nava J, et al. (March 2001). "Efficacy and tolerability of piperacillin/tazobactam versus ceftazidime in association with amikacin for treating nosocomial pneumonia in intensive care patients: a prospective randomized multicenter trial". Intensive Care Medicine. 27 (3): 493–502. doi:10.1007/s001340000846. PMID 11355117. S2CID 587826.
Joshi M, Metzler M, McCarthy M, Olvey S, Kassira W, Cooper A (September 2006). "Comparison of piperacillin/tazobactam and imipenem/cilastatin, both in combination with tobramycin, administered every 6 h for treatment of nosocomial pneumonia". Respiratory Medicine. 100 (9): 1554–65. doi:10.1016/j.rmed.2006.01.004. PMID 16487695.
Schmitt DV, Leitner E, Welte T, Lode H (June 2006). "Piperacillin/tazobactam vs imipenem/cilastatin in the treatment of nosocomial pneumonia--a double blind prospective multicentre study". Infection. 34 (3): 127–34. doi:10.1007/s15010-006-5020-0. PMID 16804655. S2CID 43485365.
Lau WK, Mercer D, Itani KM, Nicolau DP, Kuti JL, Mansfield D, et al. (November 2006). "Randomized, open-label, comparative study of piperacillin-tazobactam administered by continuous infusion versus intermittent infusion for treatment of hospitalized patients with complicated intra-abdominal infection". Antimicrobial Agents and Chemotherapy. 50 (11): 3556–61. doi:10.1128/AAC.00329-06. PMC 1635208. PMID 16940077.
Kaufman SE, Donnell RW, Hickey WS (August 2011). "Rationale and evidence for extended infusion of piperacillin-tazobactam". American Journal of Health-System Pharmacy. 68 (16): 1521–6. doi:10.2146/ajhp100694. PMID 21817083.
Wolf MF, Simon A (January 2009). "The use of piperacillin-tazobactam in neonatal and paediatric patients". Expert Opinion on Drug Metabolism & Toxicology. 5 (1): 57–69. doi:10.1517/17425250802614688. PMID 19236229. S2CID 72928444.
Gin A, Dilay L, Karlowsky JA, Walkty A, Rubinstein E, Zhanel GG (June 2007). "Piperacillin-tazobactam: a beta-lactam/beta-lactamase inhibitor combination". Expert Review of Anti-Infective Therapy. 5 (3): 365–83. doi:10.1586/14787210.5.3.365. PMID 17547502. S2CID 68837323.
Benli A, Şimşek-Yavuz S, Başaran S, Çağatay A, Özsüt H, Eraksoy H (November 2018). "Hematologic Adverse Effects of Prolonged Piperacillin-Tazobactam Use in Adults". Turkish Journal of Haematology. 35 (4): 290–295. doi:10.4274/tjh.2018.0127. PMC 6256823. PMID 29856362.
Zarychanski R, Wlodarczyk K, Ariano R, Bow E (July 2006). "Pharmacokinetic interaction between methotrexate and piperacillin/tazobactam resulting in prolonged toxic concentrations of methotrexate". The Journal of Antimicrobial Chemotherapy. 58 (1): 228–30. doi:10.1093/jac/dkl196. PMID 16717053.
Iven H, Brasch H (1986). "Influence of the antibiotics piperacillin, doxycycline, and tobramycin on the pharmacokinetics of methotrexate in rabbits". Cancer Chemotherapy and Pharmacology. 17 (3): 218–22. doi:10.1007/BF00256687. PMID 3742705. S2CID 25441195.
Wilke MS, Lovering AL, Strynadka NC (October 2005). "Beta-lactam antibiotic resistance: a current structural perspective". Current Opinion in Microbiology. 8 (5): 525–33. doi:10.1016/j.mib.2005.08.016. PMID 16129657.
Samaha-Kfoury JN, Araj GF (November 2003). "Recent developments in beta lactamases and extended spectrum beta lactamases". BMJ. 327 (7425): 1209–13. doi:10.1136/bmj.327.7425.1209. PMC 274061. PMID 14630759.
Yang Y, Rasmussen BA, Shlaes DM (August 1999). "Class A beta-lactamases--enzyme-inhibitor interactions and resistance". Pharmacology & Therapeutics. 83 (2): 141–51. doi:10.1016/S0163-7258(99)00027-3. PMID 10511459.
Hayashi Y, Roberts JA, Paterson DL, Lipman J (August 2010). "Pharmacokinetic evaluation of piperacillin-tazobactam". Expert Opinion on Drug Metabolism & Toxicology. 6 (8): 1017–31. doi:10.1517/17425255.2010.506187. PMID 20636224. S2CID 38067522.
Rybkine T, Mainardi JL, Sougakoff W, Collatz E, Gutmann L (July 1998). "Penicillin-binding protein 5 sequence alterations in clinical isolates of Enterococcus faecium with different levels of beta-lactam resistance". The Journal of Infectious Diseases. 178 (1): 159–63. doi:10.1086/515605. PMID 9652435.
Palmer SM, Rybak MJ (April 1997). "An evaluation of the bactericidal activity of ampicillin/sulbactam, piperacillin/tazobactam, imipenem or nafcillin alone and in combination with vancomycin against methicillin-resistant Staphylococcus aureus (MRSA) in time-kill curves with infected fibrin clots". The Journal of Antimicrobial Chemotherapy. 39 (4): 515–8. doi:10.1093/jac/39.4.515. PMID 9145825.
Grebe T, Hakenbeck R (April 1996). "Penicillin-binding proteins 2b and 2x of Streptococcus pneumoniae are primary resistance determinants for different classes of beta-lactam antibiotics". Antimicrobial Agents and Chemotherapy. 40 (4): 829–34. doi:10.1128/AAC.40.4.829. PMC 163214. PMID 8849235.
Rice LB, Carias LL, Hujer AM, Bonafede M, Hutton R, Hoyen C, et al. (February 2000). "High-level expression of chromosomally encoded SHV-1 beta-lactamase and an outer membrane protein change confer resistance to ceftazidime and piperacillin-tazobactam in a clinical isolate of Klebsiella pneumoniae". Antimicrobial Agents and Chemotherapy. 44 (2): 362–7. doi:10.1128/AAC.44.2.362-367.2000. PMC 89684. PMID 10639363.
Poole K (September 2004). "Resistance to beta-lactam antibiotics". Cellular and Molecular Life Sciences. 61 (17): 2200–23. doi:10.1007/s00018-004-4060-9. PMC 11138534. PMID 15338052. S2CID 25289147.
Aronoff GR, Sloan RS, Brier ME, Luft FC (1983). "The effect of piperacillin dose on elimination kinetics in renal impairment". European Journal of Clinical Pharmacology. 24 (4): 543–7. doi:10.1007/BF00609901. PMID 6222908. S2CID 262219.
Sörgel F, Kinzig M (July 1994). "Pharmacokinetic characteristics of piperacillin/tazobactam". Intensive Care Medicine. 20 Suppl 3 (S3): S14-20. doi:10.1007/bf01745246. PMID 7962984. S2CID 27422742.
Welling PG, Craig WA, Bundtzen RW, Kwok FW, Gerber AU, Madsen PO (June 1983). "Pharmacokinetics of piperacillin in subjects with various degrees of renal function". Antimicrobial Agents and Chemotherapy. 23 (6): 881–7. doi:10.1128/aac.23.6.881. PMC 184992. PMID 6225390.
Wise R, Logan M, Cooper M, Andrews JM (June 1991). "Pharmacokinetics and tissue penetration of tazobactam administered alone and with piperacillin". Antimicrobial Agents and Chemotherapy. 35 (6): 1081–4. doi:10.1128/AAC.35.6.1081. PMC 284290. PMID 1656853.
Westphal JF, Brogard JM, Caro-Sampara F, Adloff M, Blicklé JF, Monteil H, et al. (August 1997). "Assessment of biliary excretion of piperacillin-tazobactam in humans". Antimicrobial Agents and Chemotherapy. 41 (8): 1636–40. doi:10.1128/aac.41.8.1636. PMC 163977. PMID 9257733.
Bryson HM, Brogden RN (March 1994). "Piperacillin/tazobactam. A review of its antibacterial activity, pharmacokinetic properties and therapeutic potential". Drugs. 47 (3): 506–35. doi:10.2165/00003495-199447030-00008. PMID 7514977. S2CID 209144038.
Kinzig M, Sörgel F, Brismar B, Nord CE (September 1992). "Pharmacokinetics and tissue penetration of tazobactam and piperacillin in patients undergoing colorectal surgery". Antimicrobial Agents and Chemotherapy. 36 (9): 1997–2004. doi:10.1128/aac.36.9.1997. PMC 192425. PMID 1329637.
Craig WA (January 1998). "Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men". Clinical Infectious Diseases. 26 (1): 1–10, quiz 11–2. doi:10.1086/516284. PMID 9455502.
Turnidge JD (July 1998). "The pharmacodynamics of beta-lactams". Clinical Infectious Diseases. 27 (1): 10–22. doi:10.1086/514622. PMID 9675443.
Burgess DS, Waldrep T (July 2002). "Pharmacokinetics and pharmacodynamics of piperacillin/tazobactam when administered by continuous infusion and intermittent dosing". Clinical Therapeutics. 24 (7): 1090–104. doi:10.1016/s0149-2918(02)80021-2. PMID 12182254.
Buck C, Bertram N, Ackermann T, Sauerbruch T, Derendorf H, Paar WD (January 2005). "Pharmacokinetics of piperacillin-tazobactam: intermittent dosing versus continuous infusion". International Journal of Antimicrobial Agents. 25 (1): 62–7. doi:10.1016/j.ijantimicag.2004.08.012. PMID 15620828.
Occhipinti DJ, Pendland SL, Schoonover LL, Rypins EB, Danziger LH, Rodvold KA (November 1997). "Pharmacokinetics and pharmacodynamics of two multiple-dose piperacillin-tazobactam regimens". Antimicrobial Agents and Chemotherapy. 41 (11): 2511–7. doi:10.1128/AAC.41.11.2511. PMC 164153. PMID 9371358.
Ong CT, Kuti JL, Nicolau DP (2005). "Pharmacodynamic modeling of imipenem-cilastatin, meropenem, and piperacillin-tazobactam for empiric therapy of skin and soft tissue infections: a report from the OPTAMA Program". Surgical Infections. 6 (4): 419–26. doi:10.1089/sur.2005.6.419. PMID 16433606.
Kotapati S, Kuti JL, Nicolau DP (2005). "Pharmacodynamic modeling of beta-lactam antibiotics for the empiric treatment of secondary peritonitis: a report from the OPTAMA program". Surgical Infections. 6 (3): 297–304. doi:10.1089/sur.2005.6.297. PMID 16201939.
Maglio D, Kuti JL, Nicolau DP (July 2005). "Simulation of antibiotic pharmacodynamic exposure for the empiric treatment of nosocomial bloodstream infections: a report from the OPTAMA program". Clinical Therapeutics. 27 (7): 1032–42. doi:10.1016/j.clinthera.2005.07.004. PMID 16154482.
Sun HK, Kuti JL, Nicolau DP (October 2005). "Pharmacodynamics of antimicrobials for the empirical treatment of nosocomial pneumonia: a report from the OPTAMA Program". Critical Care Medicine. 33 (10): 2222–7. doi:10.1097/01.CCM.0000181528.88571.9B. PMID 16215374. S2CID 27349260.
Mattoes HM, Capitano B, Kim MK, Xuan D, Quintiliani R, Nightingale CH, et al. (May 2002). "Comparative pharmacokinetic and pharmacodynamic profile of piperacillin/tazobactam 3.375G Q4H and 4.5G Q6H". Chemotherapy. 48 (2): 59–63. doi:10.1159/000057663. PMID 12011536. S2CID 25721950.
Li C, Kuti JL, Nightingale CH, Mansfield DL, Dana A, Nicolau DP (August 2005). "Population pharmacokinetics and pharmacodynamics of piperacillin/tazobactam in patients with complicated intra-abdominal infection". The Journal of Antimicrobial Chemotherapy. 56 (2): 388–95. doi:10.1093/jac/dki243. PMID 16002420.
Lodise TP, Lomaestro BM, Drusano GL (September 2006). "Application of antimicrobial pharmacodynamic concepts into clinical practice: focus on beta-lactam antibiotics: insights from the Society of Infectious Diseases Pharmacists". Pharmacotherapy. 26 (9): 1320–32. doi:10.1592/phco.26.9.1320. PMID 16945055. S2CID 196393077.
Lodise TP, Lomaestro B, Rodvold KA, Danziger LH, Drusano GL (December 2004). "Pharmacodynamic profiling of piperacillin in the presence of tazobactam in patients through the use of population pharmacokinetic models and Monte Carlo simulation". Antimicrobial Agents and Chemotherapy. 48 (12): 4718–24. doi:10.1128/AAC.48.12.4718-4724.2004. PMC 529233. PMID 15561849.
Reese AM, Frei CR, Burgess DS (August 2005). "Pharmacodynamics of intermittent and continuous infusion piperacillin/tazobactam and cefepime against extended-spectrum beta-lactamase-producing organisms". International Journal of Antimicrobial Agents. 26 (2): 114–9. doi:10.1016/j.ijantimicag.2005.06.004. PMID 16029947.
Essack SY (2001). "The Development of β-Lactam Antibiotics in Response to the Evolution of β-Lactamases 6". Pharmaceutical Research. 18 (10): 1391–1399. doi:10.1023/A:1012272403776. PMID 11697463. S2CID 34318096.

ncbi.nlm.nih.gov

Zhanel GG, DeCorby M, Laing N, Weshnoweski B, Vashisht R, Tailor F, et al. (April 2008). "Antimicrobial-resistant pathogens in intensive care units in Canada: results of the Canadian National Intensive Care Unit (CAN-ICU) study, 2005-2006". Antimicrobial Agents and Chemotherapy. 52 (4): 1430–7. doi:10.1128/AAC.01538-07. PMC 2292546. PMID 18285482.
Lau WK, Mercer D, Itani KM, Nicolau DP, Kuti JL, Mansfield D, et al. (November 2006). "Randomized, open-label, comparative study of piperacillin-tazobactam administered by continuous infusion versus intermittent infusion for treatment of hospitalized patients with complicated intra-abdominal infection". Antimicrobial Agents and Chemotherapy. 50 (11): 3556–61. doi:10.1128/AAC.00329-06. PMC 1635208. PMID 16940077.
Benli A, Şimşek-Yavuz S, Başaran S, Çağatay A, Özsüt H, Eraksoy H (November 2018). "Hematologic Adverse Effects of Prolonged Piperacillin-Tazobactam Use in Adults". Turkish Journal of Haematology. 35 (4): 290–295. doi:10.4274/tjh.2018.0127. PMC 6256823. PMID 29856362.
Samaha-Kfoury JN, Araj GF (November 2003). "Recent developments in beta lactamases and extended spectrum beta lactamases". BMJ. 327 (7425): 1209–13. doi:10.1136/bmj.327.7425.1209. PMC 274061. PMID 14630759.
Grebe T, Hakenbeck R (April 1996). "Penicillin-binding proteins 2b and 2x of Streptococcus pneumoniae are primary resistance determinants for different classes of beta-lactam antibiotics". Antimicrobial Agents and Chemotherapy. 40 (4): 829–34. doi:10.1128/AAC.40.4.829. PMC 163214. PMID 8849235.
Rice LB, Carias LL, Hujer AM, Bonafede M, Hutton R, Hoyen C, et al. (February 2000). "High-level expression of chromosomally encoded SHV-1 beta-lactamase and an outer membrane protein change confer resistance to ceftazidime and piperacillin-tazobactam in a clinical isolate of Klebsiella pneumoniae". Antimicrobial Agents and Chemotherapy. 44 (2): 362–7. doi:10.1128/AAC.44.2.362-367.2000. PMC 89684. PMID 10639363.
Poole K (September 2004). "Resistance to beta-lactam antibiotics". Cellular and Molecular Life Sciences. 61 (17): 2200–23. doi:10.1007/s00018-004-4060-9. PMC 11138534. PMID 15338052. S2CID 25289147.
Welling PG, Craig WA, Bundtzen RW, Kwok FW, Gerber AU, Madsen PO (June 1983). "Pharmacokinetics of piperacillin in subjects with various degrees of renal function". Antimicrobial Agents and Chemotherapy. 23 (6): 881–7. doi:10.1128/aac.23.6.881. PMC 184992. PMID 6225390.
Wise R, Logan M, Cooper M, Andrews JM (June 1991). "Pharmacokinetics and tissue penetration of tazobactam administered alone and with piperacillin". Antimicrobial Agents and Chemotherapy. 35 (6): 1081–4. doi:10.1128/AAC.35.6.1081. PMC 284290. PMID 1656853.
Westphal JF, Brogard JM, Caro-Sampara F, Adloff M, Blicklé JF, Monteil H, et al. (August 1997). "Assessment of biliary excretion of piperacillin-tazobactam in humans". Antimicrobial Agents and Chemotherapy. 41 (8): 1636–40. doi:10.1128/aac.41.8.1636. PMC 163977. PMID 9257733.
Kinzig M, Sörgel F, Brismar B, Nord CE (September 1992). "Pharmacokinetics and tissue penetration of tazobactam and piperacillin in patients undergoing colorectal surgery". Antimicrobial Agents and Chemotherapy. 36 (9): 1997–2004. doi:10.1128/aac.36.9.1997. PMC 192425. PMID 1329637.
Occhipinti DJ, Pendland SL, Schoonover LL, Rypins EB, Danziger LH, Rodvold KA (November 1997). "Pharmacokinetics and pharmacodynamics of two multiple-dose piperacillin-tazobactam regimens". Antimicrobial Agents and Chemotherapy. 41 (11): 2511–7. doi:10.1128/AAC.41.11.2511. PMC 164153. PMID 9371358.
Lodise TP, Lomaestro B, Rodvold KA, Danziger LH, Drusano GL (December 2004). "Pharmacodynamic profiling of piperacillin in the presence of tazobactam in patients through the use of population pharmacokinetic models and Monte Carlo simulation". Antimicrobial Agents and Chemotherapy. 48 (12): 4718–24. doi:10.1128/AAC.48.12.4718-4724.2004. PMC 529233. PMID 15561849.

semanticscholar.org

api.semanticscholar.org

Klastersky JA, ed. (1997). Febrile Neutropenia. Berlin, Heidelberg: Springer Berlin Heidelberg. doi:10.1007/978-3-642-60443-0. ISBN 978-3-540-61230-8. S2CID 34848917.
Westphal JF, Brogard JM (January 1999). "Biliary tract infections: a guide to drug treatment". Drugs. 57 (1): 81–91. doi:10.2165/00003495-199957010-00007. PMID 9951953. S2CID 46953299.
Perry CM, Markham A (May 1999). "Piperacillin/tazobactam: an updated review of its use in the treatment of bacterial infections". Drugs. 57 (5): 805–43. doi:10.2165/00003495-199957050-00017. PMID 10353303. S2CID 209143536.
Alvarez-Lerma F, Insausti-Ordeñana J, Jordá-Marcos R, Maraví-Poma E, Torres-Martí A, Nava J, et al. (March 2001). "Efficacy and tolerability of piperacillin/tazobactam versus ceftazidime in association with amikacin for treating nosocomial pneumonia in intensive care patients: a prospective randomized multicenter trial". Intensive Care Medicine. 27 (3): 493–502. doi:10.1007/s001340000846. PMID 11355117. S2CID 587826.
Schmitt DV, Leitner E, Welte T, Lode H (June 2006). "Piperacillin/tazobactam vs imipenem/cilastatin in the treatment of nosocomial pneumonia--a double blind prospective multicentre study". Infection. 34 (3): 127–34. doi:10.1007/s15010-006-5020-0. PMID 16804655. S2CID 43485365.
Wolf MF, Simon A (January 2009). "The use of piperacillin-tazobactam in neonatal and paediatric patients". Expert Opinion on Drug Metabolism & Toxicology. 5 (1): 57–69. doi:10.1517/17425250802614688. PMID 19236229. S2CID 72928444.
Gin A, Dilay L, Karlowsky JA, Walkty A, Rubinstein E, Zhanel GG (June 2007). "Piperacillin-tazobactam: a beta-lactam/beta-lactamase inhibitor combination". Expert Review of Anti-Infective Therapy. 5 (3): 365–83. doi:10.1586/14787210.5.3.365. PMID 17547502. S2CID 68837323.
Iven H, Brasch H (1986). "Influence of the antibiotics piperacillin, doxycycline, and tobramycin on the pharmacokinetics of methotrexate in rabbits". Cancer Chemotherapy and Pharmacology. 17 (3): 218–22. doi:10.1007/BF00256687. PMID 3742705. S2CID 25441195.
Hayashi Y, Roberts JA, Paterson DL, Lipman J (August 2010). "Pharmacokinetic evaluation of piperacillin-tazobactam". Expert Opinion on Drug Metabolism & Toxicology. 6 (8): 1017–31. doi:10.1517/17425255.2010.506187. PMID 20636224. S2CID 38067522.
Poole K (September 2004). "Resistance to beta-lactam antibiotics". Cellular and Molecular Life Sciences. 61 (17): 2200–23. doi:10.1007/s00018-004-4060-9. PMC 11138534. PMID 15338052. S2CID 25289147.
Aronoff GR, Sloan RS, Brier ME, Luft FC (1983). "The effect of piperacillin dose on elimination kinetics in renal impairment". European Journal of Clinical Pharmacology. 24 (4): 543–7. doi:10.1007/BF00609901. PMID 6222908. S2CID 262219.
Sörgel F, Kinzig M (July 1994). "Pharmacokinetic characteristics of piperacillin/tazobactam". Intensive Care Medicine. 20 Suppl 3 (S3): S14-20. doi:10.1007/bf01745246. PMID 7962984. S2CID 27422742.
Bryson HM, Brogden RN (March 1994). "Piperacillin/tazobactam. A review of its antibacterial activity, pharmacokinetic properties and therapeutic potential". Drugs. 47 (3): 506–35. doi:10.2165/00003495-199447030-00008. PMID 7514977. S2CID 209144038.
Sun HK, Kuti JL, Nicolau DP (October 2005). "Pharmacodynamics of antimicrobials for the empirical treatment of nosocomial pneumonia: a report from the OPTAMA Program". Critical Care Medicine. 33 (10): 2222–7. doi:10.1097/01.CCM.0000181528.88571.9B. PMID 16215374. S2CID 27349260.
Mattoes HM, Capitano B, Kim MK, Xuan D, Quintiliani R, Nightingale CH, et al. (May 2002). "Comparative pharmacokinetic and pharmacodynamic profile of piperacillin/tazobactam 3.375G Q4H and 4.5G Q6H". Chemotherapy. 48 (2): 59–63. doi:10.1159/000057663. PMID 12011536. S2CID 25721950.
Lodise TP, Lomaestro BM, Drusano GL (September 2006). "Application of antimicrobial pharmacodynamic concepts into clinical practice: focus on beta-lactam antibiotics: insights from the Society of Infectious Diseases Pharmacists". Pharmacotherapy. 26 (9): 1320–32. doi:10.1592/phco.26.9.1320. PMID 16945055. S2CID 196393077.
Essack SY (2001). "The Development of β-Lactam Antibiotics in Response to the Evolution of β-Lactamases 6". Pharmaceutical Research. 18 (10): 1391–1399. doi:10.1023/A:1012272403776. PMID 11697463. S2CID 34318096.